ATG7 and neoplasm: To study the impact of autophagy inhibition on mIDH1 tumor in vivo, we targeted the autophagy pathway via two approaches: i) a genetically engineered sleeping beauty model that expresses shRNA against ATG7 (shATG7; Fig. 9a and Supplementary Figs. 16, 20); and ii) pharmacological inhibition of autophagy pathway using Synthetic protein nanoparticles (SPNPs) loaded with a siRNA targeting ATG7 (ATG7i-SPNP; Fig. 9a and Supplementary Figs. 21–22).